Search results for "VIRUS"

showing 10 items of 5024 documents

Thinking of future as an older individual increases perceived risks for age‐related diseases but not for COVID‐19

2022

Actively thinking of one's future as an older individual could increase perceived risk and risk aversion. This could be particularly relevant for COVID-19, if we consider the common representation of the risk of being infected by COVID-19 as associated with being older. Increased perceived risk could bear consequences on the adoption of preventive behaviours. Thus, we investigated whether increasing the salience of individuals' future as an older adult would impact on their perceived risk for COVID-19 and medical conditions varying for age-relatedness. One hundred and forty-four Italian adults (Mage = 27.72, range: 18–56) were randomly assigned to either a future as older adult thinking or …

AdultAging2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)050109 social psychology050105 experimental psychologyDevelopmental psychologyArts and Humanities (miscellaneous)COVID‐19risk perceptionAge relatedAge priming; Age-related diseases; COVID-19; Future-oriented thinking; Risk perceptionHumansAge‐related diseases0501 psychology and cognitive sciencesGeneral PsychologyAgedage-related diseaseSalience (language)SARS-CoV-2Risk aversion05 social sciencesCOVID-19General MedicineFuture‐oriented thinkingRisk perceptionfuture-oriented thinkingCross-Sectional StudiesItalyRegular Empirical ArticleRegular Empirical ArticlesPsychologyAge-related diseasesage primingInternational Journal of Psychology
researchProduct

The Quest for Predictors of Shunt-Dependent Chronic Hydrocephalus After Aneurysmal Subarachnoid Hemorrhage: Toward a Tailored Approach for Permanent …

2021

AdultAneurysmal subarachnoid hemorrhage Cerebrospinal fluid (CSF) output External ventricular drainage Hydrocephalus Adult Cerebrospinal Fluid Shunts Chronic Disease Aged Humans Hydrocephalus Ventriculoperitoneal Shunt Predictive Value of Tests Middle Aged Subarachnoid Hemorrhage Risk Assessment Prognosis Treatment OutcomeCerebrospinal fluid (CSF) output2019-20 coronavirus outbreakmedicine.medical_specialtySubarachnoid hemorrhageCoronavirus disease 2019 (COVID-19)Aneurysmal subarachnoid hemorrhageSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Risk AssessmentVentriculoperitoneal ShuntPredictive Value of TestsmedicineHumansAgedbusiness.industryExternal ventricular drainageMiddle AgedSubarachnoid Hemorrhagemedicine.diseasePrognosisChronic hydrocephalusCerebrospinal Fluid ShuntsHydrocephalusShunt (medical)SurgeryTreatment OutcomeChronic DiseaseSurgeryNeurology (clinical)businessHydrocephalus
researchProduct

High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C

2013

SUMMARY. Soluble CD36 (sCD36) plasma levels, a known marker of cardiometabolic disorders, are associated with surrogate markers of steatosis, while experimental and human studies show a link between CD36 expression in the liver and steatosis. In a cohort of patients with genotype 1 chronic hepatitis C (G1 CHC), we tested the association of sCD36 plasma levels with host and viral factors and sustained virological response (SVR). One hundred and seventy-five consecutive biopsy-proven patients were studied. sCD36 plasma levels were assessed by an in-house ELISA. All biopsies were scored by one pathologist for staging and grading (Scheuer) and graded for steatosis, which was considered moderate…

AdultCD36 AntigensMaleGenotypeBiopsyEnzyme-Linked Immunosorbent AssayLIVER FIBROSISHepacivirusCHRONIC HEPATITIS CAntigens CD36Settore MED/08 - Anatomia PatologicaAntiviral AgentsSeverity of Illness IndexPlasmaRibavirinHumansHEPATIC STEATOSISAgedSettore MED/12 - GastroenterologiaHepatitis C ChronicMiddle AgedFatty LiverLiverBiological MarkersFemaleInterferonsCD36 HCV steatosisBiomarkersINSULIN RESISTANCE
researchProduct

Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8+ and CD4+ T-cell responses affording protection from CMV DNAemia following allogeneic hematopo…

2011

Threshold levels of CMV-specific T-cell populations presumably affording protection from active CMV infection in allo-SCT recipients have been proposed, but lack extensive validation. We quantified CMV pp65 and immediate-early 1-specific IFN-γ CD8(+) and CD4(+) T cell responses at days +30, +60 and +90 after transplantation in 133 patients, and established cutoff cell levels protecting from CMV DNAemia within the first 120 days after transplantation. No patients showing IFN-γ CD8(+) or IFN-γ CD4(+) T-cell counts1.0 and1.2 cells/μL, respectively, developed a subsequent episode of CMV DNAemia. Initial or recurrent episodes of CMV DNAemia occurred in the face of IFN-γ T-cell levels below defin…

AdultCD4-Positive T-LymphocytesMaleAdolescentGlobulinT cellCytomegalovirusCD8-Positive T-LymphocytesImmediate-Early ProteinsViral Matrix ProteinsInterferon-gammamedicineHumansTransplantation HomologousAgedTransplantationCd4 t cellbiologyUmbilical Cord Blood Transplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologyCmv dnaemiaMiddle AgedPhosphoproteinsTransplantationHaematopoiesismedicine.anatomical_structureCytomegalovirus InfectionsDNA ViralImmunologybiology.proteinFemaleVirus ActivationbusinessCD8Bone Marrow Transplantation
researchProduct

Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNγ CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia an…

2009

Rising levels of cytomegalovirus (CMV) DNAemia and/or pp65 antigenemia have been observed during pre-emptive ganciclovir therapy in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). We assessed the incidence of this event in our series, and investigated whether its occurrence was associated with an impairment in the CMV-specific T-cell response. A total of 36 allo-SCT recipients experienced one or more episodes of active CMV infection (n=68) that were pre-emptively treated with val(ganciclovir). Rising levels of antigenemia and DNAemia, and an isolated increase in antigenemia, were observed in 39.7 and 2.9% of all episodes, respectively. Receipt of corticost…

AdultCD4-Positive T-LymphocytesMaleGanciclovirAdolescentvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesOpportunistic Infectionsmedicine.disease_causeHerpesviridaeImmediate-Early ProteinsViral Matrix ProteinsInterferon-gammaYoung AdultAntigenBetaherpesvirinaeDrug Resistance ViralmedicineHumansTransplantation HomologousAntigens ViralGanciclovirAgedTransplantationbiologybusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologyMiddle AgedPhosphoproteinsbiology.organism_classificationmedicine.diseaseTransplantationsurgical procedures operativeCytomegalovirus InfectionsDNA ViralMutationImmunologyFemaleStem cellbusinessCD8medicine.drugBone Marrow Transplantation
researchProduct

Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue …

2013

The effect of pegylated interferon-α (IFN) add-on therapy on HBV-specific T-cell responses was evaluated in 12 patients with stable, undetectable hepatitis B virus (HBV) load under nucleos(t)ide analogue therapy. Peripheral blood mononuclear cells were isolated at week 0, 4, 8, 12, 24 and 48 of IFN add-on therapy. Quantity and quality of circulating HBV S- and core-specific CD4 and CD8 T cells were analysed ex vivo by flow cytometry. HBV S- and core-specific CD4 T-cell numbers modestly increased within 8 weeks of IFN administration (P = 0.0391 and P = 0.0195), whereas HBV-specific CD8 T cells in general showed only minor changes under IFN add-on therapy. Functionality of HBV-specific CD4 bu…

AdultCD4-Positive T-LymphocytesMaleHBsAgHepatitis B virusT cellPopulationCD8-Positive T-Lymphocytesmedicine.disease_causeAntiviral AgentsCohort StudiesHepatitis B ChronicAntigenPegylated interferonVirologymedicineCytotoxic T cellHumanseducationTransaminasesHepatitis B viruseducation.field_of_studyHepatitis B Surface AntigensHepatologybusiness.industryInterferon-alphaHepatitis BMiddle Agedmedicine.diseaseFlow CytometryVirologyHepatitis B Core AntigensInfectious Diseasesmedicine.anatomical_structureImmunologyFemalebusinessmedicine.drugJournal of viral hepatitis
researchProduct

Treatment of Patients with Chronic Type B Hepatitis and Concurrent Human Immunodeficiency Virus Infection with a Combination of Interferon Alpha and …

1989

Six patients with chronic type B hepatitis and concurrent infection with the immunodeficiency virus were treated with 600 mg azidothymidine (AZT)/day and 3 X 10(6) units of interferon-alpha (IFN-alpha) every other day for a total of 4 months. None of the patients treated lost the hepatitis B virus (HBV). HBV-DNA concentrations were not significantly influenced by this treatment. Human immunodeficiency virus (HIV) infection was also not affected except for a transient rise in CD 4-positive cells in 2 individuals, who had initially low CD 4-positive cells. Treatment did not influence the presence of HIV-Ag in the serum. In conclusion, a combination therapy of IFN and AZT does not seem to be b…

AdultCD4-Positive T-LymphocytesMaleHepatitis B virusCombination therapyHIV AntigensAlpha interferonHIV InfectionsPilot Projectsmedicine.disease_causeLeukocyte CountZidovudineAcquired immunodeficiency syndrome (AIDS)InterferonHumansMedicineHepatitisHepatitis B virusbusiness.industryGastroenterologyvirus diseasesMiddle AgedHepatitis Bmedicine.diseaseVirologyDNA ViralInterferon Type IImmunologyDrug Therapy CombinationFemaleViral diseasebusinessZidovudinemedicine.drugDigestion
researchProduct

Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis

2013

Depletion of naive T cells from donor leukapheresis products (LPs) aims at the reduction of alloreactivity, while preserving memory T-cell reactivity (for example, to pathogens). This study established the immunomagnetic depletion procedure under clean room conditions using CD45RA beads and analyzed LPs of six donors for cell composition and functional immune responses. CD45RA depletion resulted in 3.4-4.7 log (median 4.4) reduction of CD45RA(+) T cells, thereby eliminating naive and late effector T cells. B cells were also completely removed, whereas significant proportions of NK cells, monocytes and granulocytes persisted. CD45RA-depleted LPs contained effector and central memory CD4(+) a…

AdultCD4-Positive T-LymphocytesMaleHerpesvirus 4 HumanT-LymphocytesCytomegalovirusGraft vs Host DiseaseEnzyme-Linked Immunosorbent AssayCD8-Positive T-LymphocytesLymphocyte DepletionImmunophenotypingInterferon-gammaInterleukin 21ImmunophenotypingImmune systemAntigenAntigens NeoplasmHumansMedicineLeukapheresisCandidaTransplantationImmunomagnetic Separationbusiness.industryHematologyLeukapheresisFlow Cytometrymedicine.diseaseTransplantationAspergillusGraft-versus-host diseaseImmunologyLeukocyte Common AntigensbusinessCD8Bone Marrow Transplantation
researchProduct

MMP-7 promoter polymorphisms do not influence CD4+ recovery and changes in plasma viral load during antiretroviral therapy for HIV-1 infection.

2005

Summary Matrix metalloproteinase-7 (MMP-7) generates soluble Fas Ligand (FasL), which is involved in the apoptotic loss of CD4+ T cells during HIV infection. We evaluated whether two polymorphisms in MMP-7 promoter could influence CD4+ recover in response to antiretroviral therapy, and found that these polymorphisms are ineffective.

AdultCD4-Positive T-LymphocytesMaleImmunologyHuman immunodeficiency virus (HIV)HIV InfectionsMatrix metalloproteinasemedicine.disease_causeMMP-7; Fas ligand; CD4T cells; HIV infectionFas ligandPlasma viral loadGeneticsHumansMedicineMolecular BiologyGenetics (clinical)Polymorphism Geneticbusiness.industryMetalloendopeptidasesGeneral MedicineMiddle AgedViral LoadAntiretroviral therapySoluble fas ligandCD4 Lymphocyte CountAnti-Retroviral AgentsApoptosisMatrix Metalloproteinase 7ImmunologyHIV-1business
researchProduct

Influence of lifelong cumulative HIV viremia on long-term recovery of CD4+ cell count and CD4+/CD8+ ratio among patients on combination antiretrovira…

2015

OBJECTIVE We explored the impact of lifelong cumulative HIV viremia on immunological recovery during antiretroviral therapy, according to the timing of treatment initiation. METHODS We estimated lifelong cumulative HIV viremia in patients followed in the ANRS PRIMO cohort since primary infection, including 244 patients who started treatment during PHI and had at least one treatment interruption, and 218 patients who started treatment later but with no interruptions. The impact of cumulative viremia on current immunological status was analysed using linear and logistic regression models. RESULTS At the last visit on treatment, median CD4 cell count was 645 cells/μl in the early/intermittent …

AdultCD4-Positive T-LymphocytesMalePercentilemedicine.medical_specialtyTime FactorsImmunologyCD4-CD8 RatioHuman immunodeficiency virus (HIV)CD4-CD8 RatioHIV InfectionsViremiaCD8-Positive T-Lymphocytesmedicine.disease_causeLogistic regressionMedication AdherenceCohort StudiesAntiretroviral Therapy Highly ActiveInternal medicineSecondary PreventionmedicineHumansImmunology and AllergyLongitudinal StudiesProspective StudiesViremiaCd4 cell countbusiness.industrymedicine.diseaseAntiretroviral therapyCD4 Lymphocyte CountInfectious DiseasesAnti-Retroviral AgentsCohortImmunologyFemalebusinessAIDS
researchProduct